Systematic Review And Meta-Analysis Of Psoriasis Treatments.
NCT01425138
Last updated date
ABOUT THIS STUDY
This project involved a systematic literature review of published trials of treatments for
moderate-to-severe plaque psoriasis. Data was extracted from the publications on various
psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality
Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment
comparison was conducted on the extracted data.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.
- Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
Observational studies
- Trials that did not report the Physician's Global Assessment (PGA),
- Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
PsoriasisAn Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients
NCT02322580
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisUtilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis
NCT00110981
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisAssessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis
NCT01617018
- Creteil, ILE DE France
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisOral Psoriasis Treatment Adherence and Intervention Study
NCT02850900
- Winston-Salem, North Carolina
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Systematic Review And Meta-Analysis Of Psoriasis Treatments. | |||
| Official Title | Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis | |||
| Brief Summary | This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. | |||
| Detailed Description | This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria. | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Other Time Perspective: Retrospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | Moderate-to-severe plaque psoriasis published trials. | |||
| Condition | Psoriasis | |||
| Intervention | Not Provided | |||
| Study Groups/Cohorts | Psoriasis
Published data on moderate-to-severe plaque psoriasis. | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 1 | |||
| Original Estimated Enrollment | 0 | |||
| Actual Study Completion Date | June 2011 | |||
| Actual Primary Completion Date | June 2011 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: Observational studies
| |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT01425138 | |||
| Other Study ID Numbers | A3921142 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | University of Connecticut School of Pharmacy and Hartford Hospital | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | November 2018 | |||